Home > Oncology > ESMO 2020 > Lung Cancer > Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant recurrences after surgery. A subgroup analysis of the ADAURA trial shows that osimertinib significantly decreases development of brain metastases. Rates of disease recurrence after surgery and adjuvant chemotherapy remain high in patients with resectable NSCLC across disease stages and postoperative chemotherapy used. Distant recurrence, like CNS recurrence, are associated with poor prognosis. Recently, a first analysis of the phase 3 ADAURA trial demonstrated a highly significant and clinically meaningful improvement in disease-free survival (DFS) in patients with EGFR-mutated, resectable NSCLC (stage IB/II/IIIA) who were treated with adjuvant osimertinib (80 mg/day) until recurrence or for a maximum of 3 years [1]. Updated results showed that median DFS in patients (stage IB/II/IIIA) treated with osimertinib (n=339) was not yet reached versus 27.5 mo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on